Buy stock using cpf

Visit a quote page and your recently viewed tickers will be displayed here. The company said its community-acquired bacterial pneumonia antibiotic omadacycline was not inferior to the antibiotic moxifloxacin. Paratek said it plans to file a marketing application with the Food and Drug Administration as early as the first quarter of Shares of Allergan Plc and Paratek Pharmaceuticals Inc.

The companies said two Phase 3 trials of sarecycline met their primary endpoints. Allergan is planning to seek U. Food and Drug Administration approval for the drug in the second half. Allergan, Paratek Pharma report positive results in trial of acne treatment. The opportunities -- and risks -- of emerging markets have been quite evident lately. Paratek Pharmaceuticals' PRTK CEO Michael Bigham on Q1 Results - Earnings Call Transcript. Paratek's IV omadacycline effective in penetrating lung tissue and epithelial lining fluid in early-stage study.

Paratek Pharmaceuticals PRTK could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions. Value Plus A Catalyst Investing With Seneca Park Research. Merck Gets Tecos Knockback, Gottlieb Moves Towards FDA Hotseat.

Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda ACOR and Celgene CELG providing updates.

Shares of Paratek Pharmaceuticals PRTKCyclacel Pharma CYCC and Benitec Biopharma BNTC staged a double-digit surge in price on Tuesday, rising on strong trial results for treatments of pneumonia, lung cancer and a muscle-wasting disease. All three hit major highs Tuesday. Paratek stock climbed to its highest point since Septemberup Cyclacel was up Paratek Pharmaceuticals Inc NASDAQ: Stocks Under Scanner in the Biotech Space -- Paratek Pharma, Verastem, Alnylam Pharma, and Albany Molecular Research.

New Microbiology Data Reinforce Activity of Paratek's Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections. Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July. Reports First Quarter Financial Results and Provides Clinical Update. Paratek Pharmaceuticals to Report First Quarter Financial Results and Provide Update on Clinical Progress on May 4, Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China.

New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA. New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals' Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections.

Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals.

Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results. Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne. Its products include Omadacycline and Sarecycline.

The company was founded in February and is headquartered in Boston, MA. By using this site you agree to the Terms of ServicePrivacy Policyand Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U. Intraday data delayed at least 15 minutes or per exchange requirements.

Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.

US Europe Asia FX Rates Futures Range 1D 5D 1M 3M 6M 1Y 2Y FTSE 7, Latest News All Times Eastern.

6 Reasons not to Voluntary Top Up your CPF Special Account with Cash or CPF Ordinary Account

Home Investing Quotes Stocks United States PRTK Overview Compare Quotes Stock Screener Earnings Calendar Sectors Nasdaq. Watch list Create PRTK Alert. After Hours Last Updated: Jun 20, android stock market app widget Advanced Charting 1D 5D 1M 3M 6M YTD 1Y 3Y All.

Customize MarketWatch Have Watchlists? Log in to see them here or sign up to get started. Create Account … or Log In. No Items in Watchlist There are currently no items in this Watchlist. Add Ticker to Watchlist. Go to Your Watchlist. No Saved Watchlists Create a list of the investments you want to track. Create Watchlist …or try this starter list. Uh oh Something went wrong forward rates forex loading Watchlist.

No Recent Tickers Visit a quote page and your recently viewed tickers will be displayed here.

Snap-Lock 6-Inch Black Steel Stovepipe Oval to Round Boot Stove Connector

Overview Dow jones u.s. total stock market indexsm News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders. Performance 5 Day 4. ET by Tomi Kilgore. ET by Wallace Witkowski. Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment Shares of Allergan Plc and Paratek Pharmaceuticals Inc.

ET by Ciara Linnane. Allergan, Paratek Pharma report positive results in trial of acne treatment Allergan, Paratek Pharma report positive results in trial of acne treatment Mar. Stocks to watch Monday: ET by David B.

ET by Lawrence G. Stocks to watch Wednesday: FDA approves Transcept's Intermezzo insomnia drug Nov. ET by Kate Gibson.

ET by Val Brickates Kennedy. Stock futures up after data; UBS, Netflix off Sep. Stocks to watch Thursday: RIM, Rockwell Collins Sep. Transcept Pharma climbs in after-hours trade Sep. ET by Carla Mozee. Stocks to Watch Thursday: ET by Dawn Lim. Foto su forex costo shares off on FDA sleep drug queries Jul.

The Risks and Rewards of Emerging Markets The opportunities -- and risks -- of emerging markets have been quite evident lately. ET on The Wall Street Journal. Allergan, Teva Set to See Catalysts Jun. Up and Down the Ladder: The Latest Comings and Goings at Eisai, Juno and… Jun. Eight Undervalued Key Antibiotics Players Feb. The Latest Comings and Goings at Salix, Cubist and… Nov. Citing Dangers, FDA Requires Lower Doses for Some Insomnia Drugs Jan.

Interpublic Group, Transcept Pharmaceuticals: Biggest Price Gainers IPG, TSPT Sep. UBS, Netflix and More Sep. Central Pacific-Financial, Transcept Pharmaceuticals: Biggest Price Decliners CPF, TSPT Oct.

OSIR Stock Price - Osiris Therapeutics Inc. Stock Quote (U.S.: OTC) - MarketWatch

Georgia Gulf, Transcept Pharmaceuticals: Biggest Price Gainers GGC, TSPT Aug. National Financial Partners, Transcept Pharmaceuticals: Biggest Price Decliners NFP, TSPT May. Recent News Other News Press Releases 3 Top Healthcare Stocks You Haven't Thought Of Jun.

ET on Motley Fool. The 1 Antibiotic Stock To Buy Now Paratek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now May. ET on Seeking Alpha. Tracking Seth Klarman's Baupost Group Holdings - Q1 Update Tracking Seth Klarman's Baupost Group Holdings - Q1 Update May. Paratek Pharmaceuticals' PRTK CEO Michael Bigham buy stock using cpf Q1 Results - Earnings Call Transcript Paratek Pharmaceuticals' PRTK CEO Michael Bigham on Q1 Results - Earnings Call Transcript May.

Here's Why Paratek Pharmaceuticals Rose as Much as Paratek Pharma in play? The Antimicrobial Resistance Crisis The Antimicrobial Resistance Crisis Apr. Paratek's IV omadacycline effective in penetrating lung tissue and epithelial lining fluid in early-stage study Paratek's IV omadacycline effective in penetrating lung tissue and epithelial lining buy stock using cpf in early-stage study Apr. Why Paratek Pharmaceuticals PRTK Could Be Positioned for a Surge?

Way Too Risky Motif Bio: Way Too Risky Apr. A Significantly Derisked Core Buy In Biotech Paratek Pharmaceuticals: A Significantly Derisked Core Buy In Biotech Apr. Value Plus A Catalyst Investing With Seneca Park Research PRO Weekly Digest: Value Plus A Catalyst Investing With Seneca Park Research Apr. Merck Gets Tecos Knockback, Gottlieb Moves Towards FDA Hotseat Snippet Roundup: Merck Gets Tecos Knockback, Gottlieb Moves Towards FDA Hotseat Apr.

What To Watch In Q2: Upcoming Healthcare Data Releases What To Watch In Q2: Upcoming Healthcare Data Releases Apr.

Paratek PRTK Stock Continues to Rise on Positive Results Paratek Pharmaceuticals, Inc. Acorda Down on Court Ruling, Patent Challenge for CELG Drug Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda ACOR and Celgene CELG providing updates.

Why Southwestern Energy, Paratek Pharmaceuticals, and AmTrust Financial Services Jumped Today Apr. Paratek Among Stocks Surging On Trial Results Shares of Paratek Pharmaceuticals PRTKCyclacel Pharma CYCC and Benitec Biopharma BNTC staged a double-digit surge in price on Tuesday, rising on strong trial results for treatments of pneumonia, lung cancer and a muscle-wasting disease. ET on Investors Business Daily. Paratek Pharmaceuticals Inc PTRK Well on the Way to Broad Market Opportunity Following Successful Phase 3 for Omadacycline Paratek Pharmaceuticals Inc NASDAQ: Stocks Under Scanner in the Biotech Space -- Paratek Pharma, Verastem, Alnylam Pharma, and Albany Molecular Research Stocks Under Scanner in the Biotech Space -- Paratek Pharma, Verastem, Alnylam Pharma, and Albany Molecular Research Jun.

ET on PR Newswire - PRF. New Microbiology Data Reinforce Activity of Paratek's Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections New Microbiology Data Reinforce Activity of Paratek's Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections Jun. Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe May.

Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July May.

Paratek Pharmaceuticals Inc to Host Earnings Call Investor Network: Paratek Pharmaceuticals Inc to Host Earnings Call May. Reports First Quarter Financial Results and Provides Clinical Update Paratek Pharmaceuticals, Inc. Reports First Quarter Financial Results and Provides Clinical Update May. Paratek Pharmaceuticals to Report First Quarter Financial Results and Provide Update on Clinical Progress on May 4, Paratek Pharmaceuticals to Report First Quarter Financial Results and Provide Update on Clinical Progress on May 4, Apr.

Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China Apr. New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA Apr.

New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals' Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals' Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections Apr.

Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID Apr. Benitec Biopharma and Paratek Pharmaceuticals Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals Apr.

Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results Mar. Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne Mar.

Paratek Pharmaceuticals Opens New Office in King of Prussia Paratek Pharmaceuticals Opens New Office in King of Prussia Mar. Market Landscape, Challenges and Upcoming Mar.

Reports Full Year and Fourth Quarter Financial Results and Provides Clinical Update Mar. Analyst Ratings Sell Under Hold Over Buy Number of Ratings 9 Full Ratings. Benzinga's Top Initiations Oct. Benzinga's Top Initiations Feb. MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile.

Dow Jones Network WSJ. Trending Tickers Powered by AMD 5. BioDelivery Sciences International Inc.